AI assistant

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Viking Therapeutics, Inc. Director's Dealing 2021

Jan 20, 2021

31359_dirs_2021-01-19_92269692-e32a-44ad-93a3-dfc923a819cf.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Viking Therapeutics, Inc. (VKTX)
CIK: 0001607678
Period of Report: 2021-01-19

Reporting Person: ZANTE GREG (Chief Financial Officer)

Non-Derivative Transactions

Date	Security	Code	Shares	Price	A/D	Holdings After	Ownership
2021-01-19	Common Stock, par value $0.00001 per share	F	808	$6.68	Disposed	89751	Direct

Footnotes

F1: These shares were withheld by the Issuer in order to satisfy certain tax withholding obligations upon the vesting of certain shares of restricted
stock units.